Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22119623 | 0.87 | NPC1 (0.43) | TOP2ANPC1KDM4EKMT2A | |
| SCHEMBL22119541 | 0.86 | NAMPT (0.55) | MAPTNAMPTNPC1RAB9AHTT | |
| SCHEMBL30726409 | 0.85 | NAMPT (0.48) | NAMPT | |
| SCHEMBL13196376 | 0.79 | DGAT1 (0.41) | MAPTTOP2APOLBSMN1; SMN2OPRK1 | |
| SCHEMBL2771348 | 0.79 | DGAT1 (0.41) | MAPTTOP2APOLBSMN1; SMN2OPRK1 | |
| SCHEMBL3033970 | 0.76 | FDFT1 (0.55) | NPC1RAB9ASMN1; SMN2HTTTDP1 | |
| SCHEMBL27039442 | 0.76 | NAMPT (0.59) | MAPTNAMPTNPC1RAB9AHTT | |
| SCHEMBL29939762 | 0.76 | CCR1 (0.49) | MAPTNAMPTNPC1RAB9APOLB | |
| SCHEMBL22119779 | 0.76 | OPRM1 (0.42) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL22119472 | 0.76 | OPRM1 (0.38) | MAPTNPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| EP-3897631-A1 | TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | MAPT 2440/4885NAMPT 656/4885TOP2A 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.